BS_Z0AVVB1V
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 14.914586070959263
- age_years
- 6.564
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.563
- INFLAMMATORY_RESPONSE+0.550
- IL6_JAK_STAT3_SIGNALING+0.531
- INTERFERON_GAMMA_RESPONSE+0.529
- TNFA_SIGNALING_VIA_NFKB+0.495
- INTERFERON_ALPHA_RESPONSE+0.465
- IL2_STAT5_SIGNALING+0.437
- COMPLEMENT+0.428
- COAGULATION+0.421
- TGF_BETA_SIGNALING+0.390
Top 10 suppressed
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.559
- MYC_TARGETS_V2-0.484
- MYC_TARGETS_V1-0.472
- MITOTIC_SPINDLE-0.306
- DNA_REPAIR-0.274
- SPERMATOGENESIS-0.236
- UNFOLDED_PROTEIN_RESPONSE-0.136
- MTORC1_SIGNALING-0.133
- UV_RESPONSE_UP-0.116
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359409 | — | — | 0.942 |
| 2 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.941 |
| 3 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.940 |
| 4 | BS_JWSR581E | low-grade glioma | — | 0.937 |
| 5 | BS_GYXSDZ56 | pilocytic astrocytoma | — | 0.936 |
| 6 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.936 |
| 7 | BS_MF9X3PKH | low-grade glioma | — | 0.935 |
| 8 | BS_V89HGTET | pilocytic astrocytoma | — | 0.934 |
| 9 | BS_HC5M8JTC | low-grade glioma | — | 0.934 |
| 10 | SRR8518191 | — | D | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.563 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.531 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.529 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.495 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.465 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.437 | Idelalisib | — uncovered |
| COMPLEMENT | 0.428 | Inavolisib | — uncovered |
| COAGULATION | 0.421 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.377 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.373 | Inavolisib | — uncovered |
| MYOGENESIS | 0.369 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.359 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.356 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.349 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.312 | Inavolisib | — uncovered |
| HYPOXIA | 0.303 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.298 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.278 | Inavolisib | — uncovered |